BPC-157 Oral (Gut) vs Ovagen
A side-by-side research comparison of BPC-157 Oral (Gut) and Ovagen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 Oral (Gut) | Ovagen |
|---|---|---|
| Full name | BPC-157 Oral (Stable Arginine Salt) | Ovagen (Liver & GI Peptide Bioregulator) |
| Category | Gut Health | Gut Health |
| Status | Research compound | Research compound (peptide bioregulator) |
| Mechanism | Upregulates VEGF and EGF receptors in GI mucosa, promotes angiogenesis at ulcer/lesion sites, modulates nitric oxide system, and interacts with dopamine and serotonin systems in the gut-brain axis. | As a signal peptide, it is proposed to regulate gene expression in hepatic and gastrointestinal tissue, supporting protein synthesis, detoxification pathways, and gut-associated immune function. |
| Molecular weight | 1419 Da | ~ (short peptide) |
| Half-life | ~4 hours (local GI transit) | Short (peptide) |
| Bioavailability | Limited systemic absorption; primary action is local GI | Oral (encapsulated) or subcutaneous |
| Typical dose | 250-500 mcg | ~1-2 capsules/day or short injectable courses |
| Frequency | 2x daily on empty stomach | Once daily |
| Route | Oral capsule or sublingual | Oral capsule or subcutaneous |
BPC-157 Oral (Gut) reported benefits
- Gastric ulcer healing
- Esophageal repair (GERD)
- Intestinal inflammation reduction
- IBD symptom relief
- Gut-brain axis support
- NSAID damage protection
Ovagen reported benefits
- Liver function support
- Gastrointestinal tissue support
- Protein synthesis support (proposed)
- Gut-immune resilience
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.